CJC-1295 Complete Guide: Growth Hormone Releaser, Mechanism, Dosing, and Cycle Length (2026)

The Conventional Wisdom About CJC-1295 Is Missing Something Important

CJC-1295 raises GH by 2- to 10-fold and IGF-1 by up to 3-fold in clinical trials, but the 6-to-14-day elevation window that makes it famous may matter far less than the folklore claims. Primary literature reveals a more complicated, and more interesting, story.

The standard narrative goes like this: CJC-1295 with DAC is the "set it and forget it" GHRH analogue, dosed once weekly for sustained IGF-1 elevation. Its long half-life is the feature. Its clinical trial data is spectacular. End of story.

Except that narrative is incomplete in at least three ways that matter to anyone using this peptide for research or optimisation purposes. First, the clinical trial that launched CJC-1295's reputation used a single large bolus dose in healthy adults, not a repeated weekly protocol in the populations most likely to seek it out. Second, sustained GHRH receptor activation carries a specific downregulation risk that the marketing literature conspicuously avoids. Third, the competition between the DAC and no-DAC variants is routinely framed as a simple half-life comparison, when the mechanistic case for pulsatile dosing over tonic elevation is actually stronger than most guides acknowledge.

This guide is written from primary literature outward. It does not start with the protocol and work backward to justify it. It starts with the mechanism, interrogates the clinical data honestly, and arrives at dosing recommendations that reflect what the science actually says rather than what is convenient to say.

With CJC-1295, the supplier matters as much as the dose. We only list sources that publish an independent, per-batch certificate of analysis. See the ones that clear it.

Why the 6-to-14-Day Elevation Window Is Oversold

The half-life data is real. Teichman and colleagues published the landmark pharmacokinetic study in 2006 confirming that CJC-1295 produces a mean terminal half-life of 5.8 to 8.1 days in healthy adults following subcutaneous injection. Teichman et al. 2006 GH levels rose 2- to 10-fold. IGF-1 rose approximately 1.5- to 3-fold. Those numbers are legitimately impressive compared to any other subcutaneous peptide intervention.

But here is what the study design cannot tell you: whether sustained, tonic GHRH receptor stimulation over days is mechanistically equivalent to, or superior to, episodic GHRH receptor stimulation that mirrors natural pulsatile GH physiology.

The hypothalamic-pituitary axis did not evolve to receive constant GHRH stimulation. It evolved to receive pulses. Native GHRH has a plasma half-life of roughly two to three minutes before dipeptidyl peptidase IV degrades it, producing sharp, discrete stimulation events. Somatostatin then rises to terminate the GH pulse and refractory periods allow the somatotroph cells to reprime. Alba and Salvatori 2004

When GHRH receptor stimulation becomes continuous rather than pulsatile, somatotroph desensitisation is a documented phenomenon. Animal studies using continuous GHRH infusion have shown paradoxical GH suppression over time through receptor internalisation and downstream cAMP pathway attenuation. Wehrenberg et al. 1982 The Teichman trial did not run long enough at repeated dosing intervals to capture this effect in humans, which is precisely the gap that should make researchers cautious about extrapolating single-dose pharmacokinetics to long-term weekly protocols.

This does not mean CJC-1295 with DAC is ineffective. It means the 6-to-14-day elevation window is not automatically an advantage. For some research contexts and some individual physiologies, it may be a liability worth understanding before committing to a protocol.

The Actual Mechanism: GHRH, Somatotrophs, and the cAMP Signal Chain

Understanding why the pulsatility question matters requires understanding the signal chain in detail.

The hypothalamus secretes GHRH(1-44) in pulses, driven primarily by deep slow-wave sleep, caloric restriction, and exercise stimuli. GHRH travels through the hypophyseal portal circulation to the anterior pituitary and binds to the GHRH receptor (GHRHR), a G-protein-coupled receptor on somatotroph cells. Alba and Salvatori 2004

Receptor activation couples to Gs, activating adenylate cyclase and raising intracellular cyclic AMP. Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein), driving transcription of the GH gene. Simultaneously, PKA promotes calcium influx and vesicle fusion, releasing stored GH into portal blood. Korbonits and Grossman 2004

CJC-1295 binds to GHRHR with the same mechanism as native GHRH but survives long enough in circulation to maintain receptor occupancy over days rather than minutes. Two structural modifications make this possible. First, amino acid substitutions at positions 2, 8, 15, and 27 confer resistance to DPP-IV cleavage. Second, a maleimide-containing Drug Affinity Complex (DAC) linker at the C-terminus covalently bonds to Cys34 on endogenous serum albumin. Jetté 2005

The albumin bond is the pharmacological trick. Because albumin has a circulatory half-life of approximately 19 days and is abundant in plasma at roughly 40 grams per litre, CJC-1295 effectively uses the body's most common transport protein as a slow-release depot. The maleimide linkage is reversible, releasing active CJC-1295 continuously over days rather than in a single bolus. Teichman et al. 2006

What the mechanism also tells you is that GH pulse architecture is preserved in the short term. Somatostatin oscillations still occur. When somatostatin tone is high, CJC-1295-bound GHRHR still cannot drive GH release effectively. When somatostatin tone falls, the continuously available GHRH signal amplifies the pulse. This is why Ionescu and Frohman observed increased pulse amplitude rather than tonic GH elevation in pharmacokinetic studies. Ionescu and Frohman 2006

The key question that primary literature has not fully resolved is how long this pulse-amplifying, non-desensitising effect holds before continuous receptor occupancy begins to attenuate the signal. That question is relevant to anyone planning a protocol longer than a few weeks.

DAC vs. No-DAC: The Comparison Most Guides Get Wrong

The marketing framing is simple: DAC gives you a long half-life and infrequent dosing. No-DAC (also called MOD-GRF 1-29) gives you a short half-life and requires daily or twice-daily injections. Choose based on your preference for injection frequency.

That framing misses the mechanistic argument entirely.

MOD-GRF 1-29 retains the DPP-IV-resistant amino acid substitutions of CJC-1295 but lacks the albumin-binding DAC linker. Without the linker, plasma half-life is approximately 30 minutes rather than 6 to 8 days. Jetté 2005 Each injection produces a discrete GHRH stimulation event, after which the receptor is unstimulated until the next injection. This maps much more closely onto the physiological pulsatile pattern that the pituitary evolved to receive.

The contrarian argument is not that MOD-GRF 1-29 produces larger GH pulses, it probably does not in direct comparison. The argument is that repeated pulsatile stimulation over weeks may maintain GHRHR sensitivity better than continuous DAC-mediated stimulation. This is mechanistically coherent and supported by the G-protein-coupled receptor desensitisation literature, even if no long-term head-to-head human trial directly confirms it for CJC-1295 specifically.

With CJC-1295, the supplier matters as much as the dose. We only list sources that publish an independent, per-batch certificate of analysis. See the ones that clear it.

See also the dedicated breakdown in CJC-1295 dosage: DAC vs. no-DAC for a more granular protocol comparison.

What the Clinical Trial Data Actually Shows (and What It Cannot)

The Teichman 2006 study remains the most cited piece of evidence for CJC-1295's efficacy in humans, and it is worth reading more carefully than most summaries suggest. Teichman et al. 2006

The study enrolled healthy adults and administered single subcutaneous doses ranging from 30 to 60 micrograms per kilogram of body weight. Key findings included:

• Mean GH levels rose 2- to 10-fold above baseline across dose cohorts, with peak increases observed within hours of injection
• IGF-1 levels rose approximately 1.5- to 3-fold and remained elevated for 6 to 14 days
• The pharmacokinetic profile showed a mean terminal half-life of 5.8 to 8.1 days
• Tolerability was acceptable, with injection site reactions being the most common adverse event
• No serious adverse events were reported

What the study cannot tell you:

• Whether repeated weekly dosing over 12 to 24 weeks maintains the same fold-change in GH and IGF-1 seen with a single dose
• Whether the population most likely to seek CJC-1295 (individuals over 40 with declining somatotroph function) responds comparably to the healthy young adult cohort enrolled
• Whether the IGF-1 elevation translates to the body composition, recovery, or longevity outcomes that are the practical motivation for most research use
• Long-term safety data beyond the study window

This is not a criticism of the study. It was a well-designed phase one trial doing exactly what phase one trials are supposed to do: establish pharmacokinetics and safety in a controlled population. The problem is that the peptide community has treated single-dose phase one pharmacokinetics as if they were long-term efficacy data for chronic protocols. They are not the same thing.

The honest summary is that CJC-1295 has good short-term pharmacokinetic data and plausible mechanistic rationale for chronic benefit, but the long-term repeated-dose human data that would close the loop on whether pituitary sensitisation is maintained over weeks does not exist in published form.

Dosing and Protocol Considerations for Research Purposes

The following dosing information is provided for educational purposes only. Any use of CJC-1295 in a human research context should be supervised by a qualified clinician. This content does not constitute medical advice.

CJC-1295 with DAC

The Teichman trial used weight-based dosing of 30 to 60 micrograms per kilogram. In practical research contexts, most protocols use fixed doses of 1,000 to 2,000 micrograms per injection, administered one to two times per week subcutaneously. The lower end of this range (1,000 mcg once weekly) is more conservative and aligns with the desensitisation concerns outlined above, providing a washout window between doses.

Injection timing is less critical with the DAC variant than with MOD-GRF 1-29 because the albumin reservoir releases active peptide continuously regardless of when the injection was administered. That said, many researchers inject in the evening to loosely align the release profile with overnight GH secretion patterns.

MOD-GRF 1-29 (CJC-1295 without DAC)

Because the half-life is approximately 30 minutes, timing matters considerably more with this variant. Standard research protocols use 100 to 300 micrograms per injection, administered subcutaneously. The pre-sleep injection window takes advantage of the natural nocturnal GH surge and low somatostatin tone. A second injection 30 to 60 minutes before intense training is also used to amplify the exercise-induced GH pulse.

Pairing MOD-GRF 1-29 with a GHRP (growth hormone-releasing peptide) such as ipamorelin is the most studied combination approach. GHRP compounds suppress somatostatin acutely, widening the window for GHRH-driven GH release and producing synergistic rather than merely additive GH elevation. Bowers 1998 For a detailed protocol comparison, see the guide on the CJC-1295 ipamorelin stack protocol.

Protocol Length and the Desensitisation Question

Standard community protocols run 8 to 16 weeks. The 16-week upper boundary is loosely derived from the idea that IGF-1 levels should be allowed to return toward baseline during off periods to prevent receptor-level adaptation. This is mechanistically plausible reasoning but not supported by prospective human trial data specifically for CJC-1295.

The more conservative position, consistent with the desensitisation literature on GPCR systems generally, is to consider 8-week protocols with equivalent off periods, particularly when using the DAC variant where continuous receptor occupancy is a genuine concern over longer time horizons.

Side Effects: What Primary Literature Actually Documents

The tolerability profile of CJC-1295 in human clinical data is generally favourable, with the caveat that the trial database is limited in size and duration. The following adverse effects are documented in the Teichman 2006 study and consistent with the GHRH analogue pharmacology class.

Water retention and soft tissue oedema: GH stimulates renal sodium reabsorption and promotes extracellular fluid expansion. The 2- to 10-fold GH elevation seen in the trial produces measurable fluid shifts in some individuals, particularly in the first weeks of a protocol. This is the most commonly reported subjective effect in research use contexts and is generally transient as the axis finds a new equilibrium.

Injection site reactions: Redness, mild swelling, and transient discomfort at the subcutaneous injection site were the most frequently reported adverse events in the Teichman cohort. These were dose-dependent and resolved without intervention.

Headache and flushing: Transient post-injection headache and vasodilation-related flushing were reported at higher dose levels. These are consistent with acute GH and IGF-1 elevation and the downstream nitric oxide effects of IGF-1 on vascular tone.

Insulin sensitivity considerations: Elevated GH opposes insulin action at the cellular level through inhibition of IRS-1 signalling. While CJC-1295 does not produce the supraphysiological GH levels associated with clinically significant insulin resistance in acromegaly, chronic elevation of GH even within the 2- to 10-fold trial range warrants monitoring of fasting glucose and insulin in individuals with pre-existing metabolic risk factors. A qualified clinician should assess this before and during any extended protocol.

Theoretical desensitisation: As outlined above, this is not directly documented in human CJC-1295 trials but is mechanistically supported by the broader GPCR literature and by animal data on continuous GHRH infusion. Monitoring IGF-1 levels across a protocol period is the most practical way to detect if the expected elevation is attenuating over time.

What the data does not support: significant suppression of endogenous GHRH production, axis shutdown analogous to exogenous HGH use, or negative effects on cortisol, TSH, or LH at the doses studied. CJC-1295 acts upstream of the pituitary's own secretory apparatus rather than replacing it, which is the fundamental reason its safety profile differs from direct GH administration.

How CJC-1295 Fits into a Broader Longevity and Anti-Ageing Framework

GH and IGF-1 decline roughly 14 to 15 percent per decade after peak levels in early adulthood, a phenomenon sometimes called somatopause. By the fifth and sixth decades of life, GH pulse amplitude and IGF-1 levels are substantially lower than in youth, and this decline correlates with changes in body composition, bone density, sleep architecture, and cognitive function. Corpas et al. 1993

CJC-1295 is mechanistically positioned to address somatopause by restoring GHRH signalling strength rather than bypassing the pituitary entirely. In a 40-year-old with declining somatotroph function, the pituitary may still have significant reserve capacity that native GHRH simply fails to fully activate because the hypothalamic GHRH output has diminished. Providing exogenous GHRH stimulation through a durable analogue like CJC-1295 is therefore a more targeted intervention than exogenous GH replacement.

The practical anti-ageing and longevity applications most commonly researched include improvements in body composition (lean mass preservation, adipose reduction), sleep quality driven by GH's role in slow-wave sleep architecture, connective tissue and bone density support through IGF-1-mediated collagen synthesis, and recovery from training or injury through GH-driven cellular repair pathways.

For a broader context on where CJC-1295 fits among anti-ageing peptide options, the best peptides for anti-ageing and longevity 2026 guide provides a comparative overview, and the best peptides for men over 40 covers the practical protocol considerations for the demographic most likely to be researching GH secretagogues.

Stacking CJC-1295: What the Evidence Supports

CJC-1295 in isolation targets only one of the two primary inputs to pituitary GH secretion: GHRH receptor activation. The other major input is ghrelin receptor (GHSR) activation, stimulated by ghrelin and its synthetic analogues, the GHRPs. Somatostatin is the primary inhibitory input. A mechanistically complete approach to GH axis amplification addresses all three simultaneously.

CJC-1295 plus ipamorelin: This is the most widely researched combination. Ipamorelin is a selective GHSR agonist that amplifies GH release and acutely suppresses somatostatin without the cortisol and prolactin elevation seen with earlier GHRPs like GHRP-2 and GHRP-6. Johansen et al. 1999 The combination produces synergistic GH release that exceeds either compound alone, which is why it has become the standard reference combination in peptide research. The full protocol considerations are covered in the CJC-1295 ipamorelin guide.

CJC-1295 plus BPC-157: BPC-157 is a regenerative pentadecapeptide with distinct mechanisms centred on growth factor upregulation, nitric oxide signalling, and angiogenesis rather than direct GH axis effects. These two peptides do not interact at the receptor level, making them pharmacologically compatible for concurrent research use when both GH axis optimisation and tissue repair are research objectives. See the broader recovery context in BPC-157 and TB-500 post-surgery recovery.

CJC-1295 plus GHK-Cu: GHK-Cu (copper peptide) operates through copper-dependent transcription factor modulation and wound healing pathways rather than the GH axis. Some researchers combine them in anti-ageing protocols for their complementary mechanisms. The GHK-Cu complete guide covers its distinct mechanism in detail.

What the evidence does not support: combining CJC-1295 with another long-acting GHRH analogue (stacking DAC with DAC, for instance) or with compounds that chronically suppress somatostatin, as this risks pushing GH output outside physiological ranges in ways that have not been studied for long-term safety.

Reconstitution, Storage, and Research Use Practical Notes

CJC-1295 is supplied as a lyophilised (freeze-dried) powder, typically in 2 mg or 5 mg vials. Reconstitution requires bacteriostatic water. The standard approach is to inject bacteriostatic water slowly down the side of the vial rather than directly onto the lyophilised pellet to minimise mechanical degradation of the peptide. Swirl gently rather than shaking. For a detailed step-by-step process, see the how to reconstitute peptides guide.

Once reconstituted, CJC-1295 should be stored at 2 to 8 degrees Celsius and used within 28 to 30 days. Lyophilised, unreconstituted vials are stable at room temperature for short transit periods but should be refrigerated for storage and are stable frozen for longer periods prior to reconstitution.

Injection is subcutaneous, typically into the lower abdominal fat tissue, with rotation of injection sites to prevent localised lipodystrophy. A 29 or 31-gauge insulin syringe is standard for subcutaneous administration.

All research use of CJC-1295 should be conducted under appropriate oversight. This material is provided for educational purposes relating to the pharmacology of GHRH analogues. Qualified clinician guidance is essential before any human use.

The Regulatory and Legal Context in 2026

CJC-1295 occupies a complex regulatory position. It is not approved by the FDA as a therapeutic agent. In the United States, it is sold legally by research peptide suppliers under the research use only designation, meaning it is sold for laboratory and investigational use rather than for human administration. The compounding pharmacy pathway that previously allowed some peptides to reach clinical settings has been subject to ongoing FDA scrutiny, with significant rule changes affecting the peptide compounding landscape. The FDA reclassification guide covers the regulatory evolution in detail.

WADA includes GH-releasing peptides and GHRH analogues on its prohibited list for competitive athletes. Anyone subject to anti-doping testing should consult the full prohibited list before researching any GH secretagogue. The peptides legal again 2026 update provides current context on the regulatory landscape.

With CJC-1295, the supplier matters as much as the dose. We only list sources that publish an independent, per-batch certificate of analysis. See the ones that clear it.

The Bottom Line: What CJC-1295 Actually Is and Is Not

CJC-1295 is a genuine pharmacological innovation. The DAC albumin-binding technology is mechanistically elegant. The Teichman trial data is legitimately impressive for a subcutaneous peptide intervention. The GHRH-amplification approach is a more physiologically coherent strategy for addressing somatopause than exogenous GH replacement.

But the conventional framing, in which CJC-1295 with DAC is straightforwardly superior because of its long half-life, understates the mechanistic complexity. Sustained GHRH receptor activation is not self-evidently better than episodic pulsatile activation. The clinical trial data, impressive as it is, comes from single-dose studies in healthy young adults. The long-term repeated-dose desensitisation question is real and unresolved in the human literature.

The contrarian position is not that CJC-1295 is ineffective. It is that the MOD-GRF 1-29 variant, often dismissed as the inferior no-DAC option, has a mechanistic rationale that deserves more serious consideration than the standard half-life comparison provides. And that anyone planning a sustained CJC-1295 protocol should be aware that the primary literature supports the short-term pharmacokinetics with much more confidence than it supports the long-term protocol assumptions the community has built around them.

For research use, educational purposes, and under the guidance of a qualified clinician, CJC-1295 remains one of the most pharmacologically interesting GHRH analogues available. The goal of this guide is to equip researchers with the mechanistic and clinical context to use it intelligently rather than on faith in a half-life number.